Abstract 286P
Background
Recurrent tumors on MRI described as intermediate T2 signal intensity and ADC quantitative values derived from diffusion sequences are prone to discrepancy. In post surgical setting of oral cavity ADC values are prone to artifacts limiting its utility. This investigation aims to build a decision model using quantitative robust parameters derived from MR imaging.
Methods
Four lesion quantitative parameters ( quantitative T2 lesion signal, T2 lesion/muscle signal ratio, T2 lesion /Tongue signal ratio and ADC values) were assessed in 68 lesions (54 malignant,14 benign). Classification analysis was performed using L1 regularization of features in a Logistic regression, Statistical feature selection methods like ANOVA f-value and chi square and lastly a Entropy based feature selection using decision tree. Results include the probability for malignancy for every descriptor combination in the classification tree. Area under the curve (AUC) used as the statistical parameters to find model efficiency was calculated using software "R".
Results
Logistic regression based classifier could predict the probability of cancer based on T2 based features alone. ADC was not found helpful in predicting the disease. Both scores obtained from ANOVA and Chi-square have a different assumptions about distributions of input feature values and output probabilities, but yielded different scores. Both methods point to T2 as most significant in predicting output probabilities of cancer. Lastly, the decision tree showed T2 based features in addition to ADC provide maximum diagnostic value in determining cancer in patients. The area under the curve of the ROC was .940 for additive T2 and ADC and only 0.74 for ADC values alone. The signal ratios (T2 lesion/muscle signal ratio and T2 lesion /Tongue signal ratio) have an AUC 0.96.
Conclusions
Though each method of feature selection has certain shortfalls due to the assumptions but results demonstrate T2 feature outranking all others, indicating its high predictive power in determining the probability of disease. It is therefore possible to train predictive robust models based on T2 quantitative features with high level of accuracy and precision.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session